Tumor volume analysis in clinical oncology.

CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #4023 Background : RECIST 'Response Evaluation Criteria in Solid Tumors' uses the longest diameter to measure Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD). When the diameter of a sphere doubles the volume increases eight times (Volume = 4/3 Π r3). We have previously proposed that data be expressed as volume in cubic centimetres rather than as longest diameter in centimetres. (Poster 2021 SABCS 2007) Ref 1. Method: To investigate this further we assessed 56 patients from a primary breast cancer therapeutic trial. We then compared traditional RECIST measurements with our Tumor Volume Analysis TVA using a new device LCD calculator, (patent applied for number [GB244189][1]), which has three separate programs. (1) calculation of the volume of a mass in one or two or three diameters or dimensions. (2) volume comparison between a first and second mass shown as a difference in cubic centimetres or percentage. (3) diameter comparison as RECIST between a first and second mass shown as a difference in centimetres or percentage. Results: When data are expressed as volume in cubic centimetres the response levels are higher in percentage terms. A RECIST PR of 30% becomes volume PR of 66% Table 1. Table 2 demonstrates data we have obtained using a previous study Ref 2. When the diameter is converted into volume the response levels are higher, which was statistically significant (p< 0.05). Tumor Volume Analysis: A one dimensional sphere of 3cm in diameter has a volume of 14.14 cubic centimetres. A bidimensional ellipse of 3cm x 2cm has a volume of 6.28 cubic centimetres. A date shaped tri-dimensional mass 3cm x 2cm x 1cm has a volume of 3.14 cubic centimetres. Conclusions: This demonstrates the importance of providing three dimensional measurements of a tumor. This is particularly the case in serial measurements when treatment effects are being monitored. Ref 1 SABCS Breast Cancer Volume 106 Supplement 1 December 2007 PPS1-S302 S91 Ref 2 Polychronis et al. Lancet Oncology Volume 6, June 2005 383-391. ![][2] ![][3] Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4023. [1]: /lookup/external-ref?link_type=GEN&access_num=GB244189&atom=%2Fcanres%2F69%2F2_Supplement%2F4023.atom [2]: /embed/graphic-1.gif [3]: /embed/graphic-2.gif